Cargando…

Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial

BACKGROUND & AIMS: The first-line treatment for non-alcoholic fatty liver disease (NAFLD) is weight reduction. Several diets have been proposed, with various effects specifically on liver steatosis. This trial compared the effects of intermittent calorie restriction (the 5:2 diet) and a low-carb...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmer, Magnus, Lindqvist, Catarina, Petersson, Sven, Moshtaghi-Svensson, John, Tillander, Veronika, Brismar, Torkel B., Hagström, Hannes, Stål, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059083/
https://www.ncbi.nlm.nih.gov/pubmed/33898960
http://dx.doi.org/10.1016/j.jhepr.2021.100256
_version_ 1783681137860673536
author Holmer, Magnus
Lindqvist, Catarina
Petersson, Sven
Moshtaghi-Svensson, John
Tillander, Veronika
Brismar, Torkel B.
Hagström, Hannes
Stål, Per
author_facet Holmer, Magnus
Lindqvist, Catarina
Petersson, Sven
Moshtaghi-Svensson, John
Tillander, Veronika
Brismar, Torkel B.
Hagström, Hannes
Stål, Per
author_sort Holmer, Magnus
collection PubMed
description BACKGROUND & AIMS: The first-line treatment for non-alcoholic fatty liver disease (NAFLD) is weight reduction. Several diets have been proposed, with various effects specifically on liver steatosis. This trial compared the effects of intermittent calorie restriction (the 5:2 diet) and a low-carb high-fat diet (LCHF) on reduction of hepatic steatosis. METHODS: We conducted an open-label randomised controlled trial that included 74 patients with NAFLD randomised in a 1:1:1 ratio to 12 weeks’ treatment with either a LCHF or 5:2 diet, or general lifestyle advice from a hepatologist (standard of care; SoC). The primary outcome was reduction of hepatic steatosis as measured by magnetic resonance spectroscopy. Secondary outcomes included transient elastography, insulin resistance, blood lipids, and anthropometrics. RESULTS: The LCHF and 5:2 diets were both superior to SoC treatment in reducing steatosis (absolute reduction: LCHF: −7.2% [95% CI = −9.3 to −5.1], 5:2: −6.1% [95% CI = −8.1 to −4.2], SoC: −3.6% [95% CI = −5.8 to −1.5]) and body weight (LCHF: −7.3 kg [95% CI = −9.6 to −5.0]; 5:2: −7.4 kg [95% CI = −8.7 to −6.0]; SoC: −2.5 kg [95% CI =−3.5 to −1.5]. There was no difference between 5:2 and LCHF (p = 0.41 for steatosis and 0.78 for weight). Liver stiffness improved in the 5:2 and SoC but not in the LCHF group. The 5:2 diet was associated with reduced LDL levels and was tolerated to a higher degree than LCHF. CONCLUSIONS: The LCHF and 5:2 diets were more effective in reducing steatosis and body weight in patients with NAFLD than SoC, suggesting dietary advice can be tailored to meet individual preferences. LAY SUMMARY: For a person with obesity who suffers from fatty liver, weight loss through diet can be an effective treatment to improve the condition of the liver. Many popular diets that are recommended for weight reduction, such as high-fat diets and diets based on intermittent fasting, have not had their effects on the liver directly evaluated. This study shows that both a low-carb high-fat and the 5:2 diet are effective in treating fatty liver caused by obesity. CLINICAL TRIALS REGISTRATION: This study is registered at Clinicaltrials.gov (NCT03118310).
format Online
Article
Text
id pubmed-8059083
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80590832021-04-23 Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial Holmer, Magnus Lindqvist, Catarina Petersson, Sven Moshtaghi-Svensson, John Tillander, Veronika Brismar, Torkel B. Hagström, Hannes Stål, Per JHEP Rep Research Article BACKGROUND & AIMS: The first-line treatment for non-alcoholic fatty liver disease (NAFLD) is weight reduction. Several diets have been proposed, with various effects specifically on liver steatosis. This trial compared the effects of intermittent calorie restriction (the 5:2 diet) and a low-carb high-fat diet (LCHF) on reduction of hepatic steatosis. METHODS: We conducted an open-label randomised controlled trial that included 74 patients with NAFLD randomised in a 1:1:1 ratio to 12 weeks’ treatment with either a LCHF or 5:2 diet, or general lifestyle advice from a hepatologist (standard of care; SoC). The primary outcome was reduction of hepatic steatosis as measured by magnetic resonance spectroscopy. Secondary outcomes included transient elastography, insulin resistance, blood lipids, and anthropometrics. RESULTS: The LCHF and 5:2 diets were both superior to SoC treatment in reducing steatosis (absolute reduction: LCHF: −7.2% [95% CI = −9.3 to −5.1], 5:2: −6.1% [95% CI = −8.1 to −4.2], SoC: −3.6% [95% CI = −5.8 to −1.5]) and body weight (LCHF: −7.3 kg [95% CI = −9.6 to −5.0]; 5:2: −7.4 kg [95% CI = −8.7 to −6.0]; SoC: −2.5 kg [95% CI =−3.5 to −1.5]. There was no difference between 5:2 and LCHF (p = 0.41 for steatosis and 0.78 for weight). Liver stiffness improved in the 5:2 and SoC but not in the LCHF group. The 5:2 diet was associated with reduced LDL levels and was tolerated to a higher degree than LCHF. CONCLUSIONS: The LCHF and 5:2 diets were more effective in reducing steatosis and body weight in patients with NAFLD than SoC, suggesting dietary advice can be tailored to meet individual preferences. LAY SUMMARY: For a person with obesity who suffers from fatty liver, weight loss through diet can be an effective treatment to improve the condition of the liver. Many popular diets that are recommended for weight reduction, such as high-fat diets and diets based on intermittent fasting, have not had their effects on the liver directly evaluated. This study shows that both a low-carb high-fat and the 5:2 diet are effective in treating fatty liver caused by obesity. CLINICAL TRIALS REGISTRATION: This study is registered at Clinicaltrials.gov (NCT03118310). Elsevier 2021-02-17 /pmc/articles/PMC8059083/ /pubmed/33898960 http://dx.doi.org/10.1016/j.jhepr.2021.100256 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Holmer, Magnus
Lindqvist, Catarina
Petersson, Sven
Moshtaghi-Svensson, John
Tillander, Veronika
Brismar, Torkel B.
Hagström, Hannes
Stål, Per
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial
title Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial
title_full Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial
title_fullStr Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial
title_full_unstemmed Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial
title_short Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial
title_sort treatment of nafld with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059083/
https://www.ncbi.nlm.nih.gov/pubmed/33898960
http://dx.doi.org/10.1016/j.jhepr.2021.100256
work_keys_str_mv AT holmermagnus treatmentofnafldwithintermittentcalorierestrictionorlowcarbhighfatdietarandomisedcontrolledtrial
AT lindqvistcatarina treatmentofnafldwithintermittentcalorierestrictionorlowcarbhighfatdietarandomisedcontrolledtrial
AT peterssonsven treatmentofnafldwithintermittentcalorierestrictionorlowcarbhighfatdietarandomisedcontrolledtrial
AT moshtaghisvenssonjohn treatmentofnafldwithintermittentcalorierestrictionorlowcarbhighfatdietarandomisedcontrolledtrial
AT tillanderveronika treatmentofnafldwithintermittentcalorierestrictionorlowcarbhighfatdietarandomisedcontrolledtrial
AT brismartorkelb treatmentofnafldwithintermittentcalorierestrictionorlowcarbhighfatdietarandomisedcontrolledtrial
AT hagstromhannes treatmentofnafldwithintermittentcalorierestrictionorlowcarbhighfatdietarandomisedcontrolledtrial
AT stalper treatmentofnafldwithintermittentcalorierestrictionorlowcarbhighfatdietarandomisedcontrolledtrial